Mitsubishi UFJ Trust & Banking Corp lessened its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 10.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 92,471 shares of the medical research company's stock after selling 11,180 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned approximately 0.18% of Charles River Laboratories International worth $17,070,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. Fiduciary Financial Group LLC raised its holdings in shares of Charles River Laboratories International by 3.9% in the fourth quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company's stock worth $310,000 after acquiring an additional 63 shares during the last quarter. Pinnacle Bancorp Inc. increased its position in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after purchasing an additional 65 shares in the last quarter. M&T Bank Corp raised its stake in Charles River Laboratories International by 3.4% in the 3rd quarter. M&T Bank Corp now owns 2,001 shares of the medical research company's stock valued at $394,000 after purchasing an additional 66 shares during the last quarter. Cornerstone Investment Partners LLC lifted its holdings in Charles River Laboratories International by 3.7% in the 4th quarter. Cornerstone Investment Partners LLC now owns 1,940 shares of the medical research company's stock valued at $358,000 after purchasing an additional 69 shares in the last quarter. Finally, Metis Global Partners LLC boosted its stake in shares of Charles River Laboratories International by 4.4% during the 4th quarter. Metis Global Partners LLC now owns 1,720 shares of the medical research company's stock worth $318,000 after purchasing an additional 72 shares during the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.
Charles River Laboratories International Stock Down 0.1 %
NYSE CRL traded down $0.15 during trading hours on Wednesday, hitting $145.84. The company had a trading volume of 250,326 shares, compared to its average volume of 1,155,849. The firm's 50 day moving average is $163.95 and its 200 day moving average is $181.92. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. Charles River Laboratories International, Inc. has a fifty-two week low of $142.76 and a fifty-two week high of $264.70. The company has a market capitalization of $7.46 billion, a price-to-earnings ratio of 971.00, a P/E/G ratio of 4.54 and a beta of 1.45.
Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.50 by $0.16. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company's revenue for the quarter was down 1.1% compared to the same quarter last year. During the same quarter last year, the firm earned $2.46 earnings per share. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.
Insider Activity
In other news, EVP Joseph W. Laplume sold 4,400 shares of the firm's stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the sale, the executive vice president now directly owns 20,013 shares in the company, valued at $3,252,112.50. This trade represents a 18.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO James C. Foster purchased 6,075 shares of the business's stock in a transaction that occurred on Thursday, February 20th. The stock was acquired at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the purchase, the chief executive officer now owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. This represents a 3.42 % increase in their position. The disclosure for this purchase can be found here. Insiders own 1.30% of the company's stock.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on CRL. Barclays reduced their price objective on shares of Charles River Laboratories International from $205.00 to $166.00 and set an "equal weight" rating on the stock in a research note on Tuesday, February 18th. Citigroup upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and raised their price objective for the stock from $155.00 to $175.00 in a report on Tuesday, March 4th. UBS Group reiterated a "neutral" rating and issued a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Bank of America decreased their price target on Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating on the stock in a research note on Friday, December 13th. Finally, Redburn Atlantic raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price objective for the company in a research note on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $189.77.
Read Our Latest Analysis on Charles River Laboratories International
About Charles River Laboratories International
(
Free Report)
Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).
See Also
Before you consider Charles River Laboratories International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Charles River Laboratories International wasn't on the list.
While Charles River Laboratories International currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
